Table 5 Biological determinants for clinical worsening and overall survival

From: Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

 

Clinical worsening

Overall survival

  

Univariable analysis

Multivariable analysis

 

Univariable analysis

Multivariable analysis

 

Frequency (%)

nevents/npatients

HR (95% CI)

P value (Wald)

HR (95% CI)

P value (Wald)

nevents/npatients

HR (95% CI)

P value (Wald)

HR (95% CI)

P value (Wald)

CRP

152

  

<0.0001

 

0.012

  

0.002

 

0.048

≤50 mg l−1

84 (55%)

12/84

1

 

1

 

7/84

1

 

1

 

>50 mg l−1

68 (45%)

33/68

4.17 (2.15–8.09)

 

2.62 (1.24–5.56)

 

22/68

3.82 (1.63–8.94)

 

2.80 (1.01–7.78)

 

Procalcitonin

143

  

<0.0001

    

<0.0001

  

≤0.50 µg l−1

110 (77%)

21/110

1

   

10/110

1

   

>0.5 µg l−1

33 (23%)

23/33

5.71 (3.15–10.35)

   

18/33

7.06 (3.26–15.3)

   

Hemoglobin

157

  

0.003

    

0.06

  

<10 g dl−1

47 (30%)

22/47

2.43 (1.35–4.36)

   

14/47

2.02 (0.97–4.19)

   

≥10 g dl−1

110 (70%)

23/110

1

   

15/110

1

   

Leukocytes

157

  

0.09

    

0.57

  

<4,000

46 (29%)

11/46

0.97 (0.47–2.0)

   

8/46

1.12 (0.47–2.68)

   

4–10,000

87 (56%)

22/87

1

   

14/87

1

   

>10,000

24 (15%)

12/24

2.07 (1.02–4.18)

   

7/24

1.63 (0.66–4.04)

   

Lymphocytes

155

  

0.009

    

0.026

  

≤500

34 (22%)

16/34

2.28 (1.23–4.23)

   

11/34

2.38 (1.11–5.08)

   

>500

121 (78%)

28/121

1

   

17/121

1

   

Neutrophil/lymphocyte ratio

155

  

0.011

    

0.15

  

<7

103 (67%)

21/103

1

   

14/103

1

   

≥7

52 (33%)

23/52

2.16 (1.19–3.92)

   

14/52

1.72 (0.82–3.63)

   

Monocytes

155

  

0.0003

 

0.30

  

0.0007

 

0.34

≤200

24 (15%)

13/24

3.42 (1.77–6.59)

 

1.50 (0.70–3.21)

 

10/24

3.83 (1.77–8.31)

 

1.58 (0.62–4.07)

 

>200

131 (85%)

31/131

1

 

1

 

18/131

1

 

1

 

Fibrinogen

151

  

0.007

    

0.10

  

≤5 g l−1

83 (55%)

17/83

1

   

11/83

1

   

>5 g l−1

68 (45%)

28/68

2.29 (1.25–4.18)

   

18/68

1.88 (0.89–3.99)

   

Ferritin

129

  

0.002

    

0.0002

  

≤1,000 ng ml−1

90 (69.8%)

20/90

1

   

8/90

1

   

>1,000 ng ml−1

39 (30.2%)

20/39

2.66 (1.43–4.94)

   

16/39

5.10 (2.18–12.0)

   

D-dimer

117

  

0.15

 

0.43

  

0.025

 

0.02

≤3 µg l−1

87 (74%)

27/87

1

 

1

 

14/87

1

-

1

 

>3 µg l−1

30 (26%)

14/30

1.60 (0.84–3.05)

 

1.31 (0.67–2.52)

 

11/30

2.47 (1.12–5.46)

 

2.63 (1.15–6.01)

 

LDH

151

  

<0.0001

 

0.0285

  

0.009

 

0.61

≤250 IU l−1

78 (52%)

10/78

1

 

1

 

7/78

1

-

1

 

>250 IU l−1

73 (48%)

33/73

4.64 (2.28–9.45)

 

2.31 (1.09–4.88)

 

20/73

3.17 (1.34–7.51)

 

1.27 (0.51–3.16)

 

Albumin

150

  

<0.0001

    

0.002

  

≤30 g l−1

36 (24%)

21/36

3.73 (2.05–6.79)

   

14/36

3.35 (1.57–7.12)

   

>30 g l−1

114 (76%)

22/114

1

   

13/114

1

   

Troponin

112

  

0.0001

    

0.01

  

≤ULN

84 (75%)

19/84

1

   

11/84

1

   

>ULN

28 (25%)

18/28

3.59 (1.88–6.88)

   

12/28

2.96 (1.29–6.79)

   
  1. The sample size varied between 157 and 112 patients, depending on the availability of samples for each laboratory test. The hazard ratio corresponds to the effect size of the covariable studied on the risk of clinical worsening or death. Statistical significance was determined by Cox models using the Wald test. Due to the exploratory nature of the analyses, no formal adjustment for multiplicity was done. All tests were two sided and significance was accepted at the 5% level.
Back to article page